10-41 - thanks for the post.

Merck is certainly charging what the market will bear - and then some. If RVX receives emergency use authorization they may be revisiting their pricing model.

Once approved, Apabetalone, priced at $7 would certainly have a competitive advantage and considerable leeway in maintaining that advantage. Brazil continues to have a new daily case load in excess of 200k new patients. I did read that Brazilian health care authorities have been highly criticized for their use of experimental therapies and treatments many of which have been ineffective which may be slowing things down for RVX. However the Phase 2b trial has only 100 patients to test - certainly attainable given the caseload. Hopefully news will be out shortly.

glta